Humacyte (HUMA) Competitors

$1.13 +0.22 (+24.18%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$1.10 -0.02 (-2.21%)

As of 05/13/2026 07:59 PM Eastern

HUMA vs. GYRE, VOR, BIOA, IVA, and TLRY

Should you buy Humacyte stock or one of its competitors? MarketBeat compares Humacyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Humacyte include Gyre Therapeutics (GYRE), Vor Biopharma (VOR), BioAge Labs (BIOA), Inventiva (IVA), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry.

How does Humacyte compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Gyre Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 133.52%. Humacyte has a consensus price target of $7.57, indicating a potential upside of 570.04%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Gyre Therapeutics had 6 more articles in the media than Humacyte. MarketBeat recorded 18 mentions for Gyre Therapeutics and 12 mentions for Humacyte. Humacyte's average media sentiment score of 0.41 beat Gyre Therapeutics' score of -0.50 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gyre Therapeutics has a net margin of -5.44% compared to Humacyte's net margin of -1,998.87%. Gyre Therapeutics' return on equity of 3.13% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Humacyte	-1,998.87%	-990.48%	-74.79%

Gyre Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Humacyte. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.06	$5.03M	-$0.09	N/A
Humacyte	$2.04M	122.98	-$40.83M	-$0.20	N/A

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by insiders. Comparatively, 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Gyre Therapeutics and Humacyte tied by winning 8 of the 16 factors compared between the two stocks.

How does Humacyte compare to Vor Biopharma?

Humacyte (NASDAQ:HUMA) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Humacyte currently has a consensus price target of $7.57, indicating a potential upside of 570.04%. Vor Biopharma has a consensus price target of $41.88, indicating a potential upside of 163.20%. Given Humacyte's higher possible upside, equities analysts clearly believe Humacyte is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Humacyte had 8 more articles in the media than Vor Biopharma. MarketBeat recorded 12 mentions for Humacyte and 4 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.44 beat Humacyte's score of 0.41 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma has a net margin of 0.00% compared to Humacyte's net margin of -1,998.87%. Vor Biopharma's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-1,998.87%	-990.48%	-74.79%
Vor Biopharma	N/A	N/A	N/A

Humacyte has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

Vor Biopharma has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	122.98	-$40.83M	-$0.20	N/A
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Vor Biopharma beats Humacyte on 8 of the 15 factors compared between the two stocks.

How does Humacyte compare to BioAge Labs?

Humacyte (NASDAQ:HUMA) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Humacyte has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

44.7% of Humacyte shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 20.8% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Humacyte had 3 more articles in the media than BioAge Labs. MarketBeat recorded 12 mentions for Humacyte and 9 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.79 beat Humacyte's score of 0.41 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has a net margin of -871.75% compared to Humacyte's net margin of -1,998.87%. BioAge Labs' return on equity of -29.40% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-1,998.87%	-990.48%	-74.79%
BioAge Labs	-871.75%	-29.40%	-27.26%

Humacyte currently has a consensus price target of $7.57, indicating a potential upside of 570.04%. BioAge Labs has a consensus price target of $45.00, indicating a potential upside of 135.11%. Given Humacyte's stronger consensus rating and higher possible upside, equities analysts clearly believe Humacyte is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Humacyte has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	122.98	-$40.83M	-$0.20	N/A
BioAge Labs	$8.99M	94.64	-$80.61M	-$2.40	N/A

Summary

Humacyte beats BioAge Labs on 10 of the 16 factors compared between the two stocks.

How does Humacyte compare to Inventiva?

Humacyte (NASDAQ:HUMA) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Humacyte has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Humacyte had 10 more articles in the media than Inventiva. MarketBeat recorded 12 mentions for Humacyte and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.94 beat Humacyte's score of 0.41 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a net margin of 0.00% compared to Humacyte's net margin of -1,998.87%. Inventiva's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-1,998.87%	-990.48%	-74.79%
Inventiva	N/A	N/A	N/A

Humacyte currently has a consensus price target of $7.57, indicating a potential upside of 570.04%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 198.84%. Given Humacyte's higher probable upside, research analysts clearly believe Humacyte is more favorable than Inventiva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Humacyte has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	122.98	-$40.83M	-$0.20	N/A
Inventiva	$5.07M	159.48	-$400.67M	N/A	N/A

Summary

Inventiva beats Humacyte on 9 of the 15 factors compared between the two stocks.

How does Humacyte compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Tilray Brands had 6 more articles in the media than Humacyte. MarketBeat recorded 18 mentions for Tilray Brands and 12 mentions for Humacyte. Tilray Brands' average media sentiment score of 1.01 beat Humacyte's score of 0.41 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	10 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Humacyte has lower revenue, but higher earnings than Tilray Brands. Humacyte is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.77	-$2.19B	-$13.65	N/A
Humacyte	$2.04M	122.98	-$40.83M	-$0.20	N/A

Tilray Brands has a net margin of -156.51% compared to Humacyte's net margin of -1,998.87%. Tilray Brands' return on equity of -3.31% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Humacyte	-1,998.87%	-990.48%	-74.79%

Tilray Brands has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

Tilray Brands presently has a consensus price target of $11.50, suggesting a potential upside of 110.62%. Humacyte has a consensus price target of $7.57, suggesting a potential upside of 570.04%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Humacyte beats Tilray Brands on 9 of the 16 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMA vs. The Competition

Export

Metric	Humacyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$202.04M	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.29%	2.79%	5.30%
P/E Ratio	-5.65	18.52	20.99	25.65
Price / Sales	122.98	301.26	555.98	78.93
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	56.50	6.75	9.70	6.66
Net Income	-$40.83M	$24.11M	$3.55B	$333.63M
7 Day Performance	4.63%	-0.53%	-0.56%	-0.11%
1 Month Performance	63.51%	0.34%	1.17%	3.94%
1 Year Performance	-39.57%	78.62%	41.20%	36.07%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMA Humacyte	2.589 of 5 stars	$1.13 +24.2%	$7.57 +570.0%	-34.7%	$202.04M	$2.04M	N/A	150	Trending News Earnings Report Analyst Forecast High Trading Volume
GYRE Gyre Therapeutics	2.2559 of 5 stars	$7.92 +1.5%	$17.00 +114.6%	-36.7%	$756.55M	$116.59M	792.79	40	Analyst Downgrade Analyst Revision
VOR Vor Biopharma	2.6736 of 5 stars	$14.71 +6.2%	$50.56 +243.7%	N/A	$750.47M	N/A	N/A	140	Positive News
BIOA BioAge Labs	3.0242 of 5 stars	$16.62 -1.0%	$46.25 +178.3%	N/A	$745.14M	$8.99M	N/A	N/A	Earnings Report Analyst Forecast
IVA Inventiva	2.7983 of 5 stars	$5.27 +6.0%	$16.56 +214.1%	+54.7%	$725.38M	$5.07M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMA) Competitors

HUMA vs. GYRE, VOR, BIOA, IVA, and TLRY

How does Humacyte compare to Gyre Therapeutics?

Summary

How does Humacyte compare to Vor Biopharma?

Summary

How does Humacyte compare to BioAge Labs?

Summary

How does Humacyte compare to Inventiva?

Summary

How does Humacyte compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humacyte (HUMA) Competitors

HUMA vs. GYRE, VOR, BIOA, IVA, and TLRY

How does Humacyte compare to Gyre Therapeutics?

Do analysts recommend GYRE or HUMA?

Does the media prefer GYRE or HUMA?

Is GYRE or HUMA more profitable?

Which has more risk & volatility, GYRE or HUMA?

Which has stronger earnings & valuation, GYRE or HUMA?

Do institutionals & insiders have more ownership in GYRE or HUMA?

Summary

How does Humacyte compare to Vor Biopharma?

Do analysts rate HUMA or VOR?

Does the media refer more to HUMA or VOR?

Is HUMA or VOR more profitable?

Which has more volatility & risk, HUMA or VOR?

Which has preferable valuation & earnings, HUMA or VOR?

Do insiders and institutionals have more ownership in HUMA or VOR?

Summary

How does Humacyte compare to BioAge Labs?

Which has more volatility & risk, HUMA or BIOA?

Do insiders and institutionals have more ownership in HUMA or BIOA?

Does the media refer more to HUMA or BIOA?

Is HUMA or BIOA more profitable?

Do analysts rate HUMA or BIOA?

Which has preferable valuation & earnings, HUMA or BIOA?

Summary

How does Humacyte compare to Inventiva?

Which has more risk & volatility, HUMA or IVA?

Do institutionals and insiders have more ownership in HUMA or IVA?

Does the media refer more to HUMA or IVA?

Is HUMA or IVA more profitable?

Do analysts rate HUMA or IVA?

Which has better valuation and earnings, HUMA or IVA?

Summary

How does Humacyte compare to Tilray Brands?

Does the media prefer TLRY or HUMA?

Which has stronger earnings & valuation, TLRY or HUMA?

Is TLRY or HUMA more profitable?

Which has more risk & volatility, TLRY or HUMA?

Do analysts prefer TLRY or HUMA?

Do insiders & institutionals hold more shares of TLRY or HUMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools